# SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

> **NCT03250962** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 280 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT03250962
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-11
- **Primary completion:** 2022-07-21
- **Final completion:** 2025-03-21
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250962, "SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03250962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*